GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

If you’re 60 years of age or older, speak with your healthcare provider or pharmacist about getting vaccinated against RSV. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is the first ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...

此外，近日GSK公布其RSV疫苗在预防60岁以上老年人3年（3个完整流行季）的保护效力，累积保护效力为63%，然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%，而Arexvy的初始效力在三款疫苗中已是佼佼者。

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

制药巨头GSK和辉瑞制药公司的呼吸道合胞病毒（RSV）疫苗在美国的销量出现显著下降，这是由于监管决策影响了符合接种条件的人数。美国疾病控制和预防中心（CDC）建议75岁及以上的成年人，以及60至74岁具有特定医疗条件的人群接种RSV疫苗，这比去年60岁及以上的广泛年龄建议范围要窄。 独立药剂师报告称，今年秋季RSV疫苗的需求比去年同期下降了多达三分之二。医疗保健数据公司IQVIA的数据（在多份分析 ...